Kodiak Sciences Inc at JPMorgan Healthcare Conference Transcript
Okay. We'll go ahead and get started. I've been told from the audience that my introduction for this hasn't changed in 10 years. But I want to welcome everybody to the Tuesday morning of the 2020, JP Morgan Health Care conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JP Morgan. Matt Bannon and Tessa Romero from the team are joining me. Our first presenting company of the day is Kodiak, and presenting on behalf of the company is CEO, Victor Perlroth. Victor?
Thank you, Anupam. I'm Victor Perlroth, the CEO of Kodiak Sciences. It's my pleasure to be here. Just a quick note on our forward-looking statements before we dive in.
Our goal at Kodiak is to develop the best next-generation therapeutics for high-prevalence retinal diseases using our antibody biopolymer conjugate, or ABC Platform. And KSI-301 is our lead molecule. It's our anti-VEGF ABC and the data that we're
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
